Atrial fibrillation (AF) is the most common clinical arrhythmia. AF is associated with increased risk for stroke due to blood clots formed in the fibrillating atria. Some patient characteristics increase the likelyhood of AF and at the same time the risk of stroke when AF has developed. To reduce the risk of stroke, anticoagulation therapy is recommended in patients with AF and risk factors (such as high blood pressure, diabetes, vessel disease). However, occasional (paroxysmal) AF may occur without symptoms and remain undetected, leaving patients at risk. Aim of the prospective randomized study is to compare two management strategies for patients at increased risk for AF but without a known history of AF. Patients are seen regularly (monthly, then quarterly) for follow-up (incl. ECG recording and blood sample). One group of patients additionally receives a subcutaneous implantation of a loop recorder for continuous rhythm monitoring, while the control group remains on standard follow-up. Observation period is one year (optional extension for 3 years). The time to first diagnosis of AF is compared between groups, blood samples are analyzed for potential biomarkers of AF.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
82
subcutaneous implantation
LKH/Uniklinikum - Klinische Abteilung für Kardiologie
Graz, Austria
Time to first diagnosis of atrial fibrillation
Time frame: 12 months
Time to change in therapy based on the diagnosis of atrial fibrillation
Time frame: Baseline (0 months), 1,2,3,4,5,6,9 and 12 months
Hospitalizations
Time frame: 12 months
Change in NTproBNP serum level associated with occurrence of atrial fibrillation
Time frame: Baseline (0 months), 1,2,3,4,5,6,9 and 12 months
Death
Time frame: 12 months
Stroke
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.